Merck And AbbVie Q2: Pipeline And Dividends In Focus

Aug. 01, 2022 8:38 AM ETAbbVie Inc. (ABBV) Stock, MRK StockBMY, ABBV, MRK10 Comments

Summary

  • Both Merck and AbbVie reported their Q2 earnings last week, and this article provides a review of their earnings.
  • We like both given their strong pipeline and safe dividends.
  • For Merck, we anticipate strong performance in its cornerstone oncology franchise Keytruda to continue.
  • For AbbVie, we think the Humira concern is overblown as Skyrizi and Rinvoq continue to gain traction as a replacement.
  • This idea was discussed in more depth with members of my private investing community, Envision Early Retirement. Learn More »

Innovations in medicine Abstract Molecular Structure

MF3d/E+ via Getty Images

Thesis and Background

For readers familiar with our writings, you know that my wife and I like the healthcare sector for our early retirement accounts. We like a simple and concentrated portfolio with about one dozen holdings. And we

If you like this analysis, check out Envision Early Retirement to see our other ideas and real portfolios.

  • Receive actionable and unambiguous ideas across multiple assets.
  • Access our real-money portfolios, trade alerts, and transparent performance reporting.
  • Use our proprietary allocation strategies to isolate and control risks.

We have helped our members not only to beat S&P 500 but also avoid heavy drawdowns despite the extreme volatilities in BOTH the equity AND bond market.

Join for a 100% Risk-Free trial and see if our proven method can help you too.

This article was written by

18K Followers

Envision Research, aka Lucas Ma, has over 20+ years of investment experience and holds a Masters with in Quantitative Investment and a PhD in Mechanical Engineering with a focus on renewable energy, both from Stanford University. He also has 30+ years of hands-on experience in high-tech R&D and consulting, housing sector, credit sector, and actual portfolio management.

He leads the investing group Envision Early Retirement along with Sensor Unlimited where they offer proven solutions to generate both high income and high growth with isolated risks through dynamic asset allocation. Features include: two model portfolios - one for short-term survival/withdrawal and one for aggressive long-term growth, direct access via chat to discuss ideas, monthly updates on all holdings, tax discussions, and ticker critiques by request.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ABBV, MRK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About ABBV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ABBV

Related Stocks

SymbolLast Price% Chg
MRK
--
ABBV
--